10 results on '"Wan, Peggy"'
Search Results
2. Abstract PO-187: Atopic allergic conditions and prostate cancer risk in the Multiethnic Cohort Study
- Author
-
Wang, Anqi, primary, Wan, Peggy, additional, Marchand, Loic Le, additional, Wilkens, Lynne R, additional, and Haiman, Christopher A., additional
- Published
- 2022
- Full Text
- View/download PDF
3. Abstract PR01: The four-kallikrein panel discriminates prostate cancer and aggressive disease in a multiethnic population
- Author
-
Darst, Burcu F., primary, Wan, Peggy, additional, Chou, Alisha, additional, Vertosick, Emily, additional, Conti, David V., additional, Wilkens, Lynne, additional, Le Marchand, Loic, additional, Vickers, Andrew, additional, Lilja, Hans, additional, and Haiman, Christopher A., additional
- Published
- 2020
- Full Text
- View/download PDF
4. The Four-Kallikrein Panel Is Effective in Identifying Aggressive Prostate Cancer in a Multiethnic Population.
- Author
-
Darst, Burcu F., Chou, Alisha, Wan, Peggy, Pooler, Loreall, Xin Sheng, Vertosick, Emily A., Conti, David V., Wilkens, Lynne R., Le Marchand, Loïc, Vickers, Andrew J., Lilja, Hans G., and Haiman, Christopher A.
- Abstract
Background: The four-kallikrein (4K) panel has been demonstrated to improve prediction of aggressive prostate cancer compared with prostate-specific antigen (PSA) among men with moderately elevated PSA levels. However, the development and testing of the 4K panel has been conducted primarily in White men, with limited data in African Americans and no studies in other racial and ethnic groups. Methods: We evaluated the 4K panel in a nested case-control study among African American, Latino, Japanese, Native Hawaiian, and White men in the Multiethnic Cohort. Prediagnostic blood levels of free, intact, and total PSA and human kallikrein-related peptidase 2 were measured among 1,667 incident prostate cancer cases and 691 controls with PSA =2 ng/mL. We evaluated the discriminative ability of the 4K panel within and across all racial/ethnic groups. Results: The 4K panel enhanced discrimination of overall prostate cancer compared with free plus total PSA and total PSA alone (AUC 0.748 vs. 0.711 and 0.669, respectively). Discrimination was further enhanced for Gleason 8+ prostate cancer, aggressive prostate cancer, and death due to prostate cancer, and to a lesser degree for nonaggressive prostate cancer. Improvement of the 4K panel over PSA was observed in each population. Adding a prostate cancer polygenic risk score slightly improved upon the discriminative ability of the 4K panel. Conclusions: The superior discriminative ability of the 4K panel over PSA for overall and aggressive prostate cancer across multiethnic populations indicates the broad clinical applicability of the 4K panel. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
5. Abstract 1305: A genome-wide association study of prostate cancer in Uganda
- Author
-
Du, Zhaohui, primary, Lubmawa, Alexander, additional, Gundell, Susan, additional, Wan, Peggy, additional, Cissy, Nalukenge, additional, Proscovia, Muwanga, additional, Moses, Lutalo, additional, Deborah, Nansereko, additional, Olivia, Ndaruhutse, additional, Molly, Katuku, additional, Alexander, Lubwama, additional, Nassanga, Rosemary, additional, Masaba, Benson, additional, Kaggwa, Sam, additional, Namuguzi, Dan, additional, Kiddu, Vicky, additional, Luke, Asiimwe, additional, J, Kuteesa, additional, Henry, Dabanja M., additional, Conti, David, additional, Haiman, Christopher A., additional, and Watya, Stephen, additional
- Published
- 2017
- Full Text
- View/download PDF
6. Polygenic Risk Score Modifies Prostate Cancer Risk of Pathogenic Variants in Men of African Ancestry.
- Author
-
Hughley RW, Matejcic M, Song Z, Sheng X, Wan P, Xia L, Hart SN, Hu C, Yadav S, Lubmawa A, Kiddu V, Asiimwe F, Amanya C, Mutema G, Job K, Ssebakumba MK, Ingles SA, Hamilton AS, Couch FJ, Watya S, Conti DV, Darst BF, and Haiman CA
- Subjects
- Male, Humans, Genetic Predisposition to Disease genetics, Risk Factors, Germ-Line Mutation, Genetic Risk Score, Prostatic Neoplasms genetics
- Abstract
Prostate cancer risk is influenced by rare and common germline variants. We examined the aggregate association of rare germline pathogenic/likely pathogenic/deleterious (P/LP/D) variants in ATM, BRCA2, PALB2, and NBN with a polygenic risk score (PRS) on prostate cancer risk among 1,796 prostate cancer cases (222 metastatic) and 1,424 controls of African ancestry. Relative to P/LP/D non-carriers at average genetic risk (33%-66% of PRS), men with low (0%-33%) and high (66%-100%) PRS had Odds Ratios (ORs) for overall prostate cancer of 2.08 [95% confidence interval (CI) = 0.58-7.49] and 18.06 (95% CI = 4.24-76.84) among P/LP/D carriers and 0.57 (95% CI = 0.46-0.71) and 3.02 (95% CI = 2.53-3.60) among non-carriers, respectively. The OR for metastatic prostate cancer was 2.73 (95% CI = 0.24-30.54) and 28.99 (95% CI = 4.39-191.43) among P/LP/D carriers and 0.54 (95% CI = 0.31-0.95) and 3.22 (95% CI = 2.20-4.73) among non-carriers, for men with low and high PRS, respectively. Lifetime absolute risks of overall prostate cancer increased with PRS (low to high) from 9.8% to 51.5% in P/LP/D carriers and 5.5% to 23.9% in non-carriers. Lifetime absolute risks of metastatic prostate cancer increased with PRS from 1.9% to 18.1% in P/LP/D carriers and 0.3% to 2.2% in non-carriers These findings suggest that assessment of prostate cancer risk for rare variant carriers should include PRS status., Significance: These findings highlight the importance of considering rare and common variants to comprehensively assess prostate cancer risk in men of African ancestry., (© 2023 The Authors; Published by the American Association for Cancer Research.)
- Published
- 2023
- Full Text
- View/download PDF
7. Genetic Risk of Second Primary Cancer in Breast Cancer Survivors: The Multiethnic Cohort Study.
- Author
-
Chen F, Park SL, Wilkens LR, Wan P, Hart SN, Hu C, Yadav S, Couch FJ, Conti DV, de Smith AJ, and Haiman CA
- Subjects
- BRCA1 Protein genetics, BRCA2 Protein genetics, Cohort Studies, Female, Genes, BRCA1, Genetic Predisposition to Disease, Humans, Prospective Studies, Xeroderma Pigmentosum Group D Protein genetics, Breast Neoplasms genetics, Breast Neoplasms pathology, Cancer Survivors, Neoplasms, Second Primary genetics
- Abstract
Women who have had breast cancer in the past are at increased risk of developing a second primary cancer (SPC), including second primary breast cancer (SPBC) or a second primary non-breast cancer (SPNBC). In the Multiethnic Cohort (MEC) Study, we conducted a prospective cohort analysis in 3,223 female breast cancer survivors from five racial/ethnic populations (White, African American, Japanese American, Latino, and Native Hawaiian) to assess the association of rare pathogenic variants (PV) in 37 known cancer predisposition genes with risk of SPC. A total of 719 (22.3%) women developed SPC, of which, 323 (10.0%) were SPBC. Germline PVs in BRCA1 (HR, 2.28; 95% CI, 1.11-4.65) and ERCC2 (HR, 3.51; 95% CI, 1.29-9.54) were significantly enriched in women with SPC. In the subtype analysis for SPBC, a significant association of ERCC2 PVs (HR, 5.09; 95% CI, 1.58-16.4) and a suggestive association of BRCA2 PVs (HR, 2.24; 95% CI, 0.91-5.55) were observed. There was also a higher risk of SPNBC in carriers of BRCA1 PVs (HR, 2.98; 95% CI, 1.21-7.36). These results provide evidence that germline PVs in BRCA1, BRCA2, and ERCC2 contribute to the development of SPC in breast cancer survivors. These findings also suggest that compromised DNA repair mechanisms could be a predisposition factor for SPC in patients with breast cancer, supporting the need for closer monitoring of SPC in women carrying PVs in these genes., Significance: This multiethnic study links germline pathogenic variants in BRCA1, BRCA2, and ERCC2 to the development of second primary cancer in breast cancer survivors, providing biological insights and biomarkers to guide patient monitoring., (©2022 American Association for Cancer Research.)
- Published
- 2022
- Full Text
- View/download PDF
8. The Association of Prediagnostic Statin Use with Aggressive Prostate Cancer from the Multiethnic Cohort Study.
- Author
-
Chen F, Wan P, R Wilkens L, Le Marchand L, and A Haiman C
- Subjects
- Cohort Studies, Humans, Incidence, Male, Prostate, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Prostatic Neoplasms epidemiology
- Abstract
Background: There is a growing body of evidence supporting the protective effect of statins on the risk of prostate cancer, in particular aggressive disease. Past research has mostly been conducted in North American cohorts of White men., Methods: In the multiethnic cohort (MEC), we investigated the association of prediagnostic statin use with the incidence and mortality of prostate cancer across five racial/ethnic groups (White, African American, Japanese American, Latino, and Native Hawaiian)., Results: Among 31,062 male participants who completed a detailed medication questionnaire, 31.4% reported use of statins, 2,748 developed prostate cancer, and 261 died from the disease. After adjusting for potential confounders, prediagnostic statin use was associated with a 32% lower risk of fatal prostate cancer [95% confidence interval (CI) = 0.50-0.91], with the inverse association suggested consistently across the five racial/ethnic groups. Moreover, an 11% lower risk of aggressive prostate cancer (95% CI = 0.76-1.03) was observed in statin users than in nonusers. We found no statistically significant association between prediagnostic statin use and total prostate cancer or nonaggressive disease. Prediagnostic statin use was suggestively associated with a 19% reduction in prostate cancer-specific mortality (95% CI = 0.59-1.10) and an 8% reduction in all-cause mortality (95% CI = 0.79-1.07)., Conclusions: In the MEC, prediagnostic use of statin was associated with lower risks of aggressive forms of prostate cancer., Impact: Our findings provide further support for the potential benefits of statins in reducing the risk and mortality of prostate cancer, especially aggressive disease., (©2022 American Association for Cancer Research.)
- Published
- 2022
- Full Text
- View/download PDF
9. Evaluating genetic risk for prostate cancer among Japanese and Latinos.
- Author
-
Cheng I, Chen GK, Nakagawa H, He J, Wan P, Laurie CC, Shen J, Sheng X, Pooler LC, Crenshaw AT, Mirel DB, Takahashi A, Kubo M, Nakamura Y, Al Olama AA, Benlloch S, Donovan JL, Guy M, Hamdy FC, Kote-Jarai Z, Neal DE, Wilkens LR, Monroe KR, Stram DO, Muir K, Eeles RA, Easton DF, Kolonel LN, Henderson BE, Le Marchand L, and Haiman CA
- Subjects
- California epidemiology, Cohort Studies, Genetic Predisposition to Disease, Genome-Wide Association Study, Genotype, Hawaii epidemiology, Humans, Japan ethnology, Male, Models, Statistical, Neoplasm Staging, Polymorphism, Single Nucleotide, Prostatic Neoplasms epidemiology, Prostatic Neoplasms pathology, Risk, SEER Program, Asian People genetics, Hispanic or Latino genetics, Prostatic Neoplasms ethnology, Prostatic Neoplasms genetics
- Abstract
Background: There have been few genome-wide association studies (GWAS) of prostate cancer among diverse populations. To search for novel prostate cancer risk variants, we conducted GWAS of prostate cancer in Japanese and Latinos. In addition, we tested prostate cancer risk variants and developed genetic risk models of prostate cancer for Japanese and Latinos., Methods: Our first-stage GWAS of prostate cancer included Japanese (cases/controls = 1,033/1,042) and Latino (cases/controls = 1,043/1,057) from the Multiethnic Cohort (MEC). Significant associations from stage I (P < 1.0 × 10(-4)) were examined in silico in GWAS of prostate cancer (stage II) in Japanese (cases/controls = 1,583/3,386) and Europeans (cases/controls = 1,854/1,894)., Results: No novel stage I single-nucleotide polymorphism (SNP) outside of known risk regions reached genome-wide significance. For Japanese, in stage I, the most notable putative novel association was seen with 10 SNPs (P ≤ 8.0 × 10(-6)) at chromosome 2q33; however, this was not replicated in stage II. For Latinos, the most significant association was observed with rs17023900 at the known 3p12 risk locus (stage I: OR = 1.45; P = 7.01 × 10(-5) and stage II: OR = 1.58; P = 3.05 × 10(-7)). The majority of the established risk variants for prostate cancer, 79% and 88%, were positively associated with prostate cancer in Japanese and Latinos (stage I), respectively. The cumulative effects of these variants significantly influence prostate cancer risk (OR per allele = 1.10; P = 2.71 × 10(-25) and OR = 1.07; P = 1.02 × 10(-16) for Japanese and Latinos, respectively)., Conclusion and Impact: Our GWAS of prostate cancer did not identify novel genome-wide significant variants. However, our findings show that established risk variants for prostate cancer significantly contribute to risk among Japanese and Latinos., (©2012 AACR.)
- Published
- 2012
- Full Text
- View/download PDF
10. Breast cancer in a multiethnic cohort in Hawaii and Los Angeles: risk factor-adjusted incidence in Japanese equals and in Hawaiians exceeds that in whites.
- Author
-
Pike MC, Kolonel LN, Henderson BE, Wilkens LR, Hankin JH, Feigelson HS, Wan PC, Stram DO, and Nomura AM
- Subjects
- Aged, Cohort Studies, Female, Hawaii epidemiology, Humans, Incidence, Los Angeles epidemiology, Middle Aged, Postmenopause, Risk Factors, Asian statistics & numerical data, Breast Neoplasms epidemiology, Breast Neoplasms ethnology, Hispanic or Latino statistics & numerical data, White People statistics & numerical data
- Abstract
Few data exist on the extent to which the differences in breast cancer risk between "racial-ethnic" groups in the United States (US) are "explained" by differences in their distribution of risk factors. We have determined this for African-American (AA), native Hawaiian (NH), Japanese-American (JA), Latina-US-born (L-US), Latina-non-US-born (L-NUS), and white (W) women using prospective incidence data on 88,712 postmenopausal women recruited in 1993-1996. We identified 1,757 incident breast cancer cases through 1999 among these women (1,116 cases after excluding women with a simple hysterectomy or missing risk factor data). Data were available on seven "known" risk factors: ages at menarche and first birth; parity; age at and type of menopause; weight; hormone replacement therapy use; and alcohol consumption. The relative risks (RRs) of breast cancer (with the RR in Ws set to 1.0) for the groups were as follows: W = 1.0; AA = 0.78; NH = 1.33; JA = 0.99; L-US = 0.77; and L-NUS = 0.60. After adjustment for the risk factors, the RRs were as follows: W = 1.0; AA = 0.98; NH = 1.65; JA = 1.11; L-US = 0.95; and L-NUSB = 0.84. The slightly greater risk of the JAs compared with the Ws is in sharp contrast to the very low breast cancer rates that were observed in "traditional" Japanese women and in early Japanese migrants. The adjusted RR of NHs is 65% greater than that of Ws, and that of migrant Latinas is 16% lower than that of Ws. Elucidating the causes of the high rates in NHs is now a major focus of our efforts.
- Published
- 2002
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.